Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

How precision analytics is driving the future of pharmaceuticals, from small molecules to CRISPR gene editing.

Controversial and divisive, but Kennedy’s expertise is intended for one thing: change.

From AI, to hot-melt extrusion, continuous processing, generics, and more – check out our free eBook.

The pipeline of early-stage CRISPR therapeutics is huge, but advancing these innovations will require a multifaceted strategy.

The increasing focus on sustainability in the pharmaceutical industry amongst CDMOs reveals the key strategies and initiatives being undertaken.

Experts discuss the trends, challenges, and possibilities of cryopreservation for cell and gene – and how it can freeze time in manufacturing.